Tag: ADOCIA
ADOCIA announces the holding of its annual general meeting on June 28, 2022 in Paris – 05/20/2022 at 18:00
6:00 p.m. CEST – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and…
Adocia: annual general meeting on June 28
CL Published on 05/20/2022 at 6:54 p.m. Photo credit © Reuters …
Adocia: start of a study for BioChaperone Combo
(CercleFinance.com) – Adocia climbs 6% after the announcement by the biopharmaceutical company of a first subject treated with BioChaperone Combo in the CT046 clinical trial, one of three studies funded…
ADOCIA: Information relating to the number of shares and voting rights as of April 30, 2022 – 05/13/2022 at 6:00 p.m.
6 p.m. CEST – In accordance with the provisions of Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorité des Marchés…
Adocia on the rise after a new breakthrough in the treatment of diabetes
The Lyon-based biotech has announced the dosage of a first patient in China in the phase 3 program of its new diabetes treatment. This publication pushed the stock price up…
ADOCIA announces the dosage of the first patient in the Phase 3 program of BioChaperone® Lispro with its partner Tonghua Dongbao – 05/09/2022 at 09:00
• A first patient has been dosed as part of this large phase 3 program involving 1,300 people with type 1 or 2 diabetes in 100 clinical research centers in…
The value of the day in Paris – Adocia: launch of a phase 3 with ultra-rapid insulin BC Lispro in China – 05/09/2022 at 09:36
(AOF) – Adocia jumped 5.7% to 4.65 euros. The biotech announced the dosing of the first patient in BioChaperone Lispro’s Phase 3 program with partner Tonghua Dongbao. BC Lispro belongs…
Adocia: final phase of trials for ultra-rapid insulin – 05/09/2022 at 09:51
(CercleFinance.com) – Adocia announced on Monday the launch of a phase III trial on its ultra-rapid insulin, a project carried out in partnership with the Tonghua Dongbao group, China’s leading…
ADOCIA: Information relating to the number of shares and voting rights as of March 31, 2022 – 04/15/2022 at 6:00 p.m.
6 p.m. CEST – In accordance with the provisions of Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorité des Marchés…
Adocia: launch of three studies in diabetes – 04/11/2022 at 11:36
(CercleFinance.com) – Adocia announced on Monday the launch of three clinical studies with diabetic patients with its combination of two reference insulins. The biopharmaceutical company says it has obtained authorization…
Adocia: launch of three studies in diabetes
(CercleFinance.com) – Adocia announced on Monday the launch of three clinical studies with diabetic patients with its combination of two reference insulins. The biopharmaceutical company says it has obtained authorization…
Adocia launches three clinical studies – 04/11/2022 at 11:55
(AOF) – Adocia has launched three clinical studies with diabetic patients, in Germany, with its product BC Combo. BC Combo is an innovative combination of rapid-acting insulin Lispro (Humalog) and…